Drug intelligence / Profile preview

GD-iExo-003

Development stage: Phase 2
Lead developer: Guidon Pharmaceutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cell Therapies
Administration: Intravenous

Overview

GD-iExo-003 is an investigational exosome-based therapy comprising exosomes derived from human induced pluripotent stem cells (iPSCs). It is being developed for intravenous administration, primarily targeting acute ischemic stroke. The drug leverages the regenerative and immunomodulatory properties of iPSC-derived exosomes, which are thought to promote neuroprotection and repair in the context of cerebral ischemia. Clinical development is currently at Phase 1, with ongoing trials evaluating safety and preliminary efficacy in patients with acute ischemic stroke. There are also exploratory studies considering its use in vitiligo[1][2][3][5][6].

Other names: Exosomes Derived From Human Induced Pluripotent Stem Cell

Beyond the preview

Go deeper on GD-iExo-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GD-iExo-003.

Explore the full profile